Latest News - Verbund AG
Top Corporates Hub
Verbund AG
Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences
19.02.2026 12:05
IRVINE, Calif., February 19, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences:
Exploring the top movers within the S&P500 index during today's session.
17.02.2026 17:35
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update
15.02.2026 11:52
Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical technology stocks to invest in. On February 11, Stifel reiterated its Buy rating on Edwards Lifesciences and kept its price target at $110. Stifel made the move right after Edwards Lifesciences shared its Q4 2025 earnings on February 10. The results showed that quarterly sales […]
Can JPMorgan’s Downgrade Reshape AtriCure’s (ATRC) Competitive Moat In Cardiac Surgery Devices?
15.02.2026 09:12
AtriCure recently faced a shift in analyst sentiment when JPMorgan downgraded the company to Neutral, citing rising competitive pressure on its AtriClip device from Edwards Lifesciences’ planned surgical offering. This change highlights how competition in cardiac surgery devices can quickly alter perceptions of AtriCure’s positioning, even as other analysts maintain positive views on its prospects. We’ll now examine how JPMorgan’s concerns about Edwards Lifesciences’ competitive threat could...
EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs
11.02.2026 13:17
Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.
Edwards reports strong 2025 despite Q4 EPS miss
11.02.2026 12:44
Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.
Why The Narrative Around Edwards Lifesciences EW Is Shifting After 2026 Outlook And JenaValve Setback
11.02.2026 11:10
Behind the small move in Edwards Lifesciences’ fair value estimate from about US$97.02 to about US$97.11 is a set of fine tuned assumptions that reflect the latest 2026 outlook and the fallout from the canceled JenaValve deal. Analysts are essentially sharpening their pencils on discount rates and revenue growth rather than rewriting the story. This suggests the market is focused on execution details, not a new thesis. Stay tuned to see how you can track these incremental model shifts and...
February 2026's Undervalued Small Caps With Insider Action In Global Markets
11.02.2026 09:39
In February 2026, global markets are experiencing a dynamic shift as small-cap and value-oriented stocks make gains amid a cooling U.S. labor market and volatility in large-cap technology shares. With the S&P MidCap 400 and Russell 2000 indices showing solid performance, investors are increasingly interested in small-cap opportunities that demonstrate resilience and potential for growth. In this context, identifying a good stock often involves looking at companies with strong fundamentals...
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $103 Price Target
11.02.2026 07:15
BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $103 price target.
Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst ...
11.02.2026 05:01
Edwards Lifesciences Corp (EW) reports robust Q4 2025 results with an 11.6% sales increase, while navigating challenges in EPS and strategic spending.
Edwards Lifesciences Q4 Earnings Call Highlights
11.02.2026 03:07
Edwards Lifesciences (NYSE:EW) reported fourth-quarter and full-year 2025 results that management characterized as strong, driven by continued momentum in transcatheter aortic valve replacement (TAVR) and rapid growth in transcatheter mitral and tricuspid therapies (TMTT). The company said fourth-qu
What Are Wall Street Analysts' Target Price for Edwards Lifesciences Stock?
09.02.2026 14:47
While Edwards Lifesciences has underperformed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Is Edwards Lifesciences (EW) Share Weakness Creating A Valuation Opportunity?
06.02.2026 14:07
If you are wondering whether Edwards Lifesciences is attractively priced right now, it helps to first look past the headline share price and focus on what different valuation methods are saying. The stock recently closed at US$78.10, with a 7 day return of a 4.2% decline, a 30 day return of a 9.0% decline, and a year to date return of an 8.5% decline, while the 1 year return sits at 10.0%. Recent coverage around Edwards Lifesciences has focused on its role in the broader healthcare sector...
Estimating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
06.02.2026 14:00
Key Insights Edwards Lifesciences' estimated fair value is US$89.38 based on 2 Stage Free Cash Flow to Equity With...
Ahead of Edwards Lifesciences (EW) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
05.02.2026 14:15
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Edwards Lifesciences Corporation (EW): A Bull Case Theory
03.02.2026 02:51
We came across a bullish thesis on Edwards Lifesciences Corporation on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation’s share was trading at $81.49 as of January 29th. EW’s trailing and forward P/E were 35.90 and 28.82 respectively according to Yahoo Finance. Edwards Lifesciences Corporation provides products and […]
Edwards Lifesciences Refocuses On Core TAVR And Mitral Growth Story
02.02.2026 14:10
Edwards Lifesciences (NYSE:EW) is ending its planned acquisition of JenaValve. The company is redirecting the capital that would have gone to the deal into its internal transcatheter aortic valve replacement (TAVR) and mitral valve programs. This move reflects a shift toward developing in house platforms instead of expanding through this external transaction. Edwards Lifesciences is a major player in structural heart therapies, with TAVR and mitral valve technologies at the center of its...
Should Weakness in Edwards Lifesciences Corporation's (NYSE:EW) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
02.02.2026 14:09
It is hard to get excited after looking at Edwards Lifesciences' (NYSE:EW) recent performance, when its stock has...
Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW)
31.01.2026 14:35
Edwards Lifesciences Corporation (NYSE:EW) is one of the best healthcare stocks to buy for 2026. On January 20, Stifel raised its price target of Edwards Lifesciences Corporation (NYSE:EW) to $110 from $105 while reiterating a Buy rating. The price target hike is in response to a significant increase in the number of Transcatheter Aortic Valve […]